Clinical trials
Anaplastic Astrocytoma clinical trials
Below are recruiting anaplastic astrocytoma clinical trials, each written for real people, not researchers. We’re tracking 17 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT04623931RecruitingPhase 2
Chemo and radiation for IDH-wildtype glioma
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
Houston, TexasAges 18 years+ - NCT06264388RecruitingPhase 2
Gene therapy plus oral drug for recurrent brain tumors
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
Miami, FloridaAges 18–75 - NCT04135807RecruitingEarly Phase 1
Implantable device test for operable brain tumor patients
This early-phase trial tests a tiny implanted device placed during brain tumor surgery. It delivers very small doses of medicine directly to the tumor area for a short time, aiming to see if this approach is safe and workable in patients with certain gliomas.
Boston, MassachusettsAges 18 years+ - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+ - NCT02800486RecruitingPhase 2
Targeted antibody plus repeat radiation for recurrent brain tumors
This trial studies giving cetuximab (a targeted antibody) directly into an artery along with repeat radiation to treat certain recurring or treatment-resistant brain tumors. It may help by delivering the drug more directly to tumor areas and testing whether this approach can control the disease after it comes back.
New York, New YorkAges 18 years+ - NCT05956821RecruitingPhase 1/Phase 2
Study drug for young people with recurring brain glioma
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
Miami, FloridaAges 1–21 - NCT07468136RecruitingPhase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas
This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.
Rochester, MinnesotaAges 18 years+ - NCT03603405RecruitingPhase 1/Phase 2
Test vaccine and radiation with chemotherapy for new brain tumor
This trial studies a gene-based treatment (HSV-tk) given with radiation and chemotherapy for people newly diagnosed with glioblastoma or anaplastic astrocytoma. It may help the new brain tumor respond better to standard treatments, though risks and benefits are still being tested.
Houston, TexasAges 18 years+ - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT04780009Recruiting
Imaging tool during brain tumor surgery
This trial tests a special camera system used during surgery to help doctors see brain tumor tissue using fluorescent light. It may help the surgeon remove more tumor while protecting healthy brain areas.
Lexington, KentuckyAges 18–90 - NCT05084430RecruitingPhase 1/Phase 2
Pembrolizumab plus M032 for recurrent brain tumors
This early-phase study tests the safety and early signs of benefit of combining pembrolizumab with M032 in people with certain aggressive brain tumors. You may be considered if you have a glioma tumor that can potentially be removed by surgery.
Birmingham, AlabamaAges 18 years+ - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Aurora, ColoradoAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Aurora, ColoradoAges 1–39 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT01269853RecruitingPhase 1/Phase 2
Bevacizumab directly into brain arteries for recurrent brain tumors
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
New York, New YorkAges 18 years+ - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65
Hear when a new Anaplastic Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Anaplastic Astrocytoma trials by city
Studies with a site in or near these metro areas.
Anaplastic Astrocytoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for anaplastic astrocytoma?
- Yes. Clin2 currently lists 17 recruiting anaplastic astrocytoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a anaplastic astrocytoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a anaplastic astrocytoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.